CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The DEEP project aims to develop a new oral liquid formulation of deferiprone for children with β-thalassaemia major and other transfusion-dependent chronic anaemias. It focuses on establishing safety and efficacy through innovative clinical studies, addressing a critical need for effective iron chelation therapy in th…
β-thalassaemia major is one of the most severe forms of chronic congenital anaemia.
The recommended treatment consists in regular blood transfusions combined with chelating therapy to remove harmful iron accumulation in the body.
The use of deferoxamine, the first chelating agent only available for subcutaneous administration is limited due to toxicity and the lack of compliance, despite its satisfactory therapeutic effects.
An oral iron chelating agent, deferiprone, was authorised in Europe in…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, LONDON
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Tunisia, Tunis
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
